Welcome and Chairs Remarks A. Kotsakis
Chairs: N. Tsoukalas, D. Papageorgiou
12.00-12.20
LBA 3 | Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
Abstract 12016 | Identifying optimized assessment of nerve damage during chemotherapy.
M. Lavdaniti
12.20-12.40
Abstract 12020 | A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care.
LBA 12004 | Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
C. Ntola
12.40-13.00 Discussion Ν. Tsoukalas, D. Papageorgiou
Chairs: A. Kotsakis, G. Rigakos
13.00-13.30
Abstract 6009 | Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Abstract 6008 | A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
LBA 6000 | Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
P. Katsaounis
13.30-14.00 Discussant A. Psyrri
Chairs: C. Kosmas, C. Panopoulos
State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
A. Stribakos
Discussion
Chairs: E. Razis, S. Labropoulos
15.40-16.10
Abstract 2000 | N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
Abstract 2013 | A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.
Abstract 2002 | Niraparib efficacy in patients with newly diagnosed glioblastoma: Clinical readout of a phase 0/2 “trigger” trial.
D. Kalapanida
16.10-16.30 Discussant E. Razis
Chairs: A. Psyrri, F. Koinis
16.30-16.50
LBA 2509 | Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial Abstract 2500 | Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.
S. Talagani
16.50-17.10
Abstract 2504 | Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.
Abstract 2506 | Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.
G. Ardavanis-Loukeris
17.10-17.30 Discussant E. Kontopodis
Chairs: A. Koutras, I. Kotteas
17.50-18.10
LBA 500 |A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy
LBA 502 | A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY Trial.
K. Rapti
18.10-18.30
LBA 507 | Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Abstract 505 | Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)
E. Chantzara
18.30-18.50 Discussant A. Nikolaidi
Chairs: V. Barbounis, E. Galani
18.50-19.10
LBA 1001 | Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 post-MONARCH trial
LBA 1002 | Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
C. Aidarinis
19.10-19.40
Abstract 1007 | Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
LBA 1000 | Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
Abstract 1021 | Τrastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
N. Asimakopoulou
19.40- 20.00 Discussant E. Saloustros
Chairs: C. Panopoulos, V. Papadopoulos
09.00-09.20
LBA 3501 | Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. Abstract 3500 | Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).
Ν. Machairas
09.20-09.40
Abstract 108 | Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.
Abstract 3503 | Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.
Μ. Avgoustidou
09.40-10.00 Discussion V. Papadopoulos
Chairs: I. Samaras, Μ. Theochari
10.00-10.20
LBA 1 | Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). LBA 4008 | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW.
M. Drizou
10.20-10.40
Abstract 4005 | NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).
Abstract 4003 | A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.
A. Markou
10.40-11.00 Discussant G. Papaxoinis
Chairs: C. Cosmas, P. Katsaounis
Unlocking the Potential: Biomarkers of Response to Antibody - Drug Conjugates V. Papadopoulos
Discussion
Chairs: E. Goga, A. Tzovaras
12.00-12.20
LBA 2 | Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
LBA 9512 | Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
A. Laskarakis
12.20-12.40
Abstract 9500 | Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study LBA 9503 | Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).
D. Ziogas
12.40-13.00 Discussant D. Bafaloukos
Chairs: A. Boutis, E. Saloustros
13.00-13.30
Abstract 10503 | Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.
Abstract 10506 | Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials.
Abstract 10512 | Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance.
A. Mala
13.30-13.40 Panel discussion
Chairs: C. Papadimitriou, M. Liontos
14.30-14.50
Abstract 5504 | Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early- stage cervical carcinoma following radical hysterectomy: Results of NRG oncology / RTOG 0724/GOG-0724.
Abstract 5511 | A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial Cancer.
E. Eleftherakis-Papaiakovou
14.50-15.20
LBA 5500 | Final Results of BRUOG354: A Randomized Phase II Trial of Nivolumab alone or in combination with Ipilimumab for People with Ovarian and other Extrarenal Clear Cell Carcinomas
Abstract 5506 | Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.
Abstract 5510 | Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).
M. Rovithi
15.20-15.40 Discussant N. Kaparelou
Chairs: A. Koumarianou, M. Nikolaou
15.40-16.00
LBA 8505 | Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
LBA 4 | Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
E-G. Fergadis
16.00-16.20
LBA 8503 | Lorlatinib vs crizotinib in treatment-naïve patients with dvanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
Abstract 8509 | KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
O. Fiste
16.20-16.40 Discussant A. Grivas
Chairs: A. Kotsakis, K. Tsapakidis
16.40-17.00
Abstract 8506 | NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).
LBA 8002 | BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM) - Results from the ETOP 13-18 trial.
D. Stefanou
17.00-17.20
Abstract 8015 | DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC) - Efficacy and safety analyzed by presence of brain metastasis.
LBA 5 | ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)
E. Karatrasoglou
17.20-17.40 Discussant A. Kyriazoglou
Chairs: K. Koutsoukos, P. Koinis
18.00-18.30
Abstract 5003 | Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).
Abstract 5010 | A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).
Abstract 10500 | Effect of polygenic risk score for clinically significant prostate cancer in a screening program: The BARCODE 1 study results.
T. Tegos
18.30-18.50
Abstract 5009 | A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial. Abstract 4502 | Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
E. Christakou
18.50-19.10
Abstract 4509 | Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.
Abstract 4508 | Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
N. Cholis
19.10-19.30 Discussant E. Lianos